Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market | Akari Therapeutics

▤ Summary

Akari Therapeutics announced a $5 million financing through a registered direct offering and concurrent private placement. The company will issue ADSs and warrants, and the deal includes more than 20% participation from directors, officers, and executive management. Some existing note holders will also convert about $2.5 million of debt into new securities. Akari plans to use the proceeds for research and development, working capital, and general corporate purposes. The financing supports the company’s oncology ADC payload platform and improves its capital structure.

$ Funding

▦ Linked Companies